The senior leadership team at Simulations Plus, Inc. includes:

Shawn O’Connor – Mr. Shawn O’Connor is Chief Executive Officer at Simulations Plus, Inc. He recently served as president, chief executive officer and a director of Entelos, a provider of unique quantitative systems pharmacology software and services to the pharmaceutical drug development market. Prior to Entelos, O’Connor served as chairman, president, and chief executive officer of Pharsight Corporation, a developer and marketer of software products and services that help pharmaceutical and biotechnology companies improve their decision-making in drug development and commercialization.



John A. DiBella, M.S. – Mr. John A. DiBella is President, Lancaster Division of Simulations Plus, Inc.. He joined the company in 2003, spending time working on the development of GastroPlus and DDDPlus software and consulting projects. Now, he leads the Simulations Plus, Lancaster division while continuing to travel the world hosting training seminars.



Thaddeus Grasela, PharmD, Ph.D. – Dr. Ted Grasela is Executive Vice President, of Cognigen, a Simulations Plus company. Ted joined Simulations Plus in the fall of 2014 as part of our acquisition of Cognigen. Ted has extensive experience in modeling and simulation, clinical pharmacology, and outcomes research. Ted has built Cognigen into a profitable industry leader in the high-quality analysis of clinical trial data, serving customers ranging from top-5 pharmaceutical companies to numerous mid- and smaller-size organizations.



John R. Kneisel, CPA – Mr. John Kneisel is Chief Financial Officer of Simulations Plus, Inc. and joined the Company in November 2013. He worked as the Western Regional Controller of Group 1 Automotive Inc. from August 2004 through October 2009. At that time he started a consulting business providing outsourced financial management services (CFO and Controller) to small to medium sized companies. In October 2010 he became the CFO of Dreamhammer, Inc. where he worked until August 2012. His career spans 30 plus years of financial management and accounting related services.



Michael B. Bolger, Ph.D. – Dr. Michael B. Bolger is Chief Scientist at Simulations Plus, Inc. He joined the company in 1996 and programmed the first version of GastroPlus in 1997. He works with our team of scientists and programmers on the continued development of modeling & simulation software programs. In addition to his role at Simulations Plus, he is currently Adjunct Full Professor of Pharmacology and Pharmaceutical Sciences at USC. In 1996, he was elected to the rank of AAAS Fellow by the American Association for the Advancement of Science.



Jill Fiedler-Kelly, M.S., FISoP– Ms. Jill Fiedler-Kelly is President, Cognigen, a Simulations Plus company.  A co-founder of Cognigen, Ms. Fiedler-Kelly has over 20 years experience in the design and implementation of pharmacometrics M&S approaches in drug development programs and in PK/PD model development. She is Adjunct Associate Professor of Pharmaceutical Sciences at the University at Buffalo and has co-authored Introduction to Population PK/PD Analysis with Nonlinear Mixed Effects Models with Joel Owen of Union University. In 2016, Ms. Fiedler-Kelly was named Fellow of the International Society of Pharmacometrics.



Robert D. Clark, Ph.D. – Dr. Robert D. Clark is Sr. Research Fellow at Simulations Plus, Inc.. He joined the company in 2010, working with the scientists on the development of ADMET Predictor and MedChem Studio. Prior to joining the company, he worked at Monsanto Co. on agrochemical screening, physiology, and SAR-guided synthesis and at Tripos, Inc. Having risen to the post of VP of Science and Research, Bob left Tripos, Inc. to found Biochemical Infometrics, an independent research and consulting company specializing in drug design. He continues to serve as an adjunct professor at Indiana University.


Brett Howell, Ph.D.  Dr. Brett Howell is President of DILIsym Services, Inc., a company developing and using DILIsym software to improve the development of safer drug therapies. He is also an associate director of the DILI-sim Initiative since its inception in 2011. In addition to overseeing DILIsym Services operations, Dr. Howell also helps guide the architecture and use of the DILIsym modeling software.


Scott Siler, Ph.D. – DrScott Q Siler, Ph.D. is the Chief Scientific Officer of DILIsym Services, Inc., a company developing and using DILIsym software to improve the development of safer drug therapies. He is also an associate director of the DILI-sim Initiative since its inception in 2011. He helps oversee the development of the DILIsym software and is also a project manager for DILIsym services projects contracted by pharmaceutical companies. In addition to his duties in helping manage and advance the business of DILIsym Services, Dr. Siler continues to be a scientific contributor to DILIsym services projects and development. Dr. Siler is leading the company’s efforts in the development and use of NAFLDsym software, computational model of nonalcoholic fatty liver disease (NAFLD) that can be used to predict efficacy for treatment modalities developed for treating NAFLD.